Japanese regulatory • Journal
|
MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene)
|
Retevmo (selpercatinib) • Jaypirca (pirtobrutinib) • gumarontinib (SCC244) • Ezharmia (valemetostat) • Ojjaara (momelotinib) • Targretin oral (bexarotene oral)